eptivA Therapeutics Ltd. published a study in PAIN showing that GLP-1 receptor agonists reduce painful diabetic peripheral neuropathy in 10.1% of people with type 2 diabetes compared to standard treatment in 35.1%
Public source
Publisher name
Public post
GLP-1 drugs could be analgesics - but they probably won't work for everyone. A new study in PAIN reports painful diabetic peripheral neuropathy (DPN) in 10.1% of people…
Company
eptivA Therapeutics Ltd.
A clinical stage biotech company utilising novel Personalized Analgesics® research to create precision pain medicines
- Industry
- Biotechnology Research
- Location
- Oxford, GB
- Company size
- 2–10 employees
About eptivA Therapeutics Ltd.
Eptiva Therapeutics is a clinical stage Biotech company transforming the way pain is treated with PERSONALIZED ANALGESICS®. We have invented novel in silico research methods to create the first precision medicine approach to pain.
See moreLatest activity
Latest activity from eptivA Therapeutics Ltd.
6 signals
Research & Knowledge
eptivA Therapeutics Ltd. published a new Nature Communications paper by Negm and colleagues examining the spinal circuitry associated with mechanical allodynia after nerve injury using two-photon calcium imaging in an ex vivo mouse somatosensory preparation.
Research & Knowledge
eptivA Therapeutics Ltd. published a new Science paper in 2026 showing that a non-hallucinogenic 5-HT2A agonist produces similar protection in preclinical models.
Capital & Finance
eptivA Therapeutics Ltd. secured a $150m financing behind the development of neridronate in CRPS.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
PERSICA PHARMACEUTICALS LIMITED
PERSICA PHARMACEUTICALS LIMITED published a Phase 1b trial showing that PP353 produced statistically significant and durable improvements in pain and disability over 12 months, along with reduced analgesic use, including opioids.
Research & Knowledge
Akelos Inc
Akelos Inc developed a proprietary series of peripherally restricted HCN1 selective inverse agonists to alleviate pain responses in a high bar rodent model of neuropathic pain.
Research & Knowledge
PILA PHARMA
PILA PHARMA published a regulatory approval for a new longer clinical trial in people with obesity using an oral TRPV1 antagonist as a potential first-in-class candidate.
Research & Knowledge
International Association for the Study of Pain
International Association for the Study of Pain published a schematic representation of a study design presented in the PAIN Featured Image by Litewczuk et al. Results confirm the essential role of capsaicin-sensitive nociceptors for heat pain.
Research & Knowledge
Drug Hunter